AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22118479 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidermal growth factor (EGF) via Gelfoam patching
Number of subjects: 291
Study 22118479 — intervention group
Group type: EXPERIMENTAL
Intervention: Edge-approximation plus Gelfoam patching
Number of subjects: 291
Study 19731125 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored message
Number of subjects: 217
Study 19731125 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic message
Number of subjects: 217
Study 19731125 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted message
Number of subjects: 217
Study 19731125 — intervention group
Group type: COMPARATOR
Intervention: Control message
Number of subjects: 217
Study 17383080 — intervention group
Group type: COMPARATOR
Intervention: BCG RIVM 2 x 10(8) CFU weekly for 6 wk
Number of subjects: 495
Study 17383080 — intervention group
Group type: COMPARATOR
Intervention: MMC 20 mg weekly for 6 wk
Number of subjects: 495
Study 17383080 — intervention group
Group type: EXPERIMENTAL
Intervention: MMC 20 mg weekly for 6 wk followed by monthly instillations for 3 yr
Number of subjects: 495
Study 15109047 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy (CBT) intervention
Number of subjects: 0
Study 15109047 — intervention group
Group type: COMPARATOR
Intervention: Control group (no additional treatment)
Number of subjects: 0
Study 11207651 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole treatment group
Number of subjects: 0
Study 11207651 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG vaccination in treated group
Number of subjects: 0
Study 11207651 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 0
Study 9669255 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate angioplasty (2 weeks)
Number of subjects: 16
Study 9669255 — intervention group
Group type: COMPARATOR
Intervention: Delayed angioplasty (3 months)
Number of subjects: 16
Study 7596767 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 Gy/10 fractions/2 weeks (group A)
Number of subjects: 162
Study 7596767 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 Gy/20 fractions/4 weeks (group B)
Number of subjects: 162
Study 7596767 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 Gy/10 fractions/2 weeks (group C)
Number of subjects: 162
Study 7596767 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 Gy/5 fractions/1 week (group D)
Number of subjects: 162
Study 3042835 — intervention group
Group type: EXPERIMENTAL
Intervention: rt-PA (70 mg with an initial bolus of 10 mg)
Number of subjects: 246
Study 3042835 — intervention group
Group type: COMPARATOR
Intervention: Urokinase (3 million units with an initial bolus of 1.5 million units)
Number of subjects: 246
Study 3042835 — intervention group
Group type: EXPERIMENTAL
Intervention: rt-PA
Number of subjects: 246
Study 3042835 — intervention group
Group type: COMPARATOR
Intervention: Urokinase
Number of subjects: 246
Study 30866910 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital impressions (3M, St. Paul, NM)
Number of subjects: 31
Study 30866910 — intervention group
Group type: COMPARATOR
Intervention: Conventional impressions (alginate)
Number of subjects: 31
Study 29362596 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrolysin (30 ml/day for 10 days)
Number of subjects: 60
Study 29362596 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 26004611 — intervention group
Group type: EXPERIMENTAL
Intervention: EMG biofeedback treatment after BTX-A injection
Number of subjects: 36
Study 26004611 — intervention group
Group type: COMPARATOR
Intervention: Botulinum toxin-A (BTX-A) injection
Number of subjects: 36
Study 23911217 — intervention group
Group type: EXPERIMENTAL
Intervention: Very low-carbohydrate (LC) diet
Number of subjects: 47
Study 23911217 — intervention group
Group type: COMPARATOR
Intervention: High-carbohydrate (HC) diet
Number of subjects: 47
Study 22094835 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg iron as ferrous sulfate
Number of subjects: 153
Study 22094835 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg iron as NaFeEDTA
Number of subjects: 153
Study 22094835 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 153
Study 19362994 — intervention group
Group type: EXPERIMENTAL
Intervention: Benfluorex (BFL) 3 tablets/day for 24 weeks
Number of subjects: 22
Study 19362994 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 22
Study 16314385 — intervention group
Group type: EXPERIMENTAL
Intervention: Pro-active call centre-based stepped treatment support
Number of subjects: 0
Study 16314385 — intervention group
Group type: EXPERIMENTAL
Intervention: Tele-care intervention
Number of subjects: 0
Study 16281462 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of Data Monitoring Committees (DMCs)
Number of subjects: 662
Study 16281462 — intervention group
Group type: EXPERIMENTAL
Intervention: Planned interim analyses
Number of subjects: 662
Study 16281462 — intervention group
Group type: EXPERIMENTAL
Intervention: At least one of DMC use or interim analyses
Number of subjects: 662
Study 16281462 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of DMC use between 2000 and 1990
Number of subjects: 662
Study 16281462 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors associated with increased DMC use
Number of subjects: 662
Study 11401971 — intervention group
Group type: EXPERIMENTAL
Intervention: MACconj (meningococcal group A+C conjugate vaccine)
Number of subjects: 195
Study 11401971 — intervention group
Group type: EXPERIMENTAL
Intervention: MACPS (meningococcal group A+C polysaccharide vaccine)
Number of subjects: 195
Study 11401971 — intervention group
Group type: EXPERIMENTAL
Intervention: MACconj booster after MACconj priming
Number of subjects: 195
Study 11401971 — intervention group
Group type: EXPERIMENTAL
Intervention: MACPS booster after MACPS priming
Number of subjects: 195
Study 8988699 — intervention group
Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate 10 mg
Number of subjects: 123
Study 8988699 — intervention group
Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate 20 mg
Number of subjects: 123
Study 8988699 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 123
Study 8215864 — intervention group
Group type: EXPERIMENTAL
Intervention: Ankle joint angle feedback and EMG biofeedback from the soleus muscle
Number of subjects: 8
Study 8215864 — intervention group
Group type: COMPARATOR
Intervention: Conventional physical therapy (PT)
Number of subjects: 8
Study 3307567 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpheniramine maleate (CM) 4.0 mg orally, 4 times daily for 4 days
Number of subjects: 36
Study 3307567 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphenhydramine hydrochloride (DH) 2 mg intranasally, 4 times daily for 5 days
Number of subjects: 36
Study 3307567 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 29740097 — intervention group
Group type: EXPERIMENTAL
Intervention: 18F-FET PET
Number of subjects: 26
Study 29740097 — intervention group
Group type: COMPARATOR
Intervention: MRI-derived gross tumor volumes (GTV)
Number of subjects: 26
Study 29740097 — intervention group
Group type: EXPERIMENTAL
Intervention: FLAIR hyperintense area
Number of subjects: 26
Study 26931331 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior transpedicular screw fixation (ATPS)
Number of subjects: 50
Study 24898640 — intervention group
Group type: EXPERIMENTAL
Intervention: Screened positive for dementia (DemTect < 9)
Number of subjects: 243
Study 23649080 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg sublingual piroxicam (two 20‐mg tablets once daily on the first and second postoperative days, followed by one 20‐mg tablet on the third postoperative day)
Number of subjects: 100
Study 23649080 — intervention group
Group type: COMPARATOR
Intervention: 150 mg oral diclofenac (50 mg thrice a day on the first, second, and third postoperative days)
Number of subjects: 100
Study 20199243 — intervention group
Group type: EXPERIMENTAL
Intervention: Local hyperthermia at 44 degrees C for 30 min a day for 3 consecutive days plus 2 additional days 2 weeks later
Number of subjects: 54
Study 20199243 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 54
Study 18814452 — intervention group
Group type: EXPERIMENTAL
Intervention: Levocetirizine 5 mg
Number of subjects: 403
Study 18814452 — intervention group
Group type: COMPARATOR
Intervention: Montelukast 10 mg
Number of subjects: 403
Study 18814452 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 403
Study 16197669 — intervention group
Group type: EXPERIMENTAL
Intervention: Fexofenadine HCl 60 mg twice daily
Number of subjects: 18
Study 16197669 — intervention group
Group type: EXPERIMENTAL
Intervention: Loratadine 10 mg once daily
Number of subjects: 18
Study 16197669 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 12114372 — intervention group
Group type: EXPERIMENTAL
Intervention: BAYx1005 (500 mg bid)
Number of subjects: 17
Study 12114372 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 10206217 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenously administered procainamide hydrochloride
Number of subjects: 70
Study 10206217 — intervention group
Group type: COMPARATOR
Intervention: Direct current shock
Number of subjects: 70
Study 7781621 — intervention group
Group type: EXPERIMENTAL
Intervention: Stricter guidelines for diagnosis and treatment of gestational diabetes
Number of subjects: 0
Study 7781621 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term follow-up evaluation for women with gestational diabetes and their children
Number of subjects: 0
Study 2193275 — intervention group
Group type: EXPERIMENTAL
Intervention: Home uterine activity monitoring and perinatal nursing support
Number of subjects: 0
Study 2193275 — intervention group
Group type: COMPARATOR
Intervention: Education regarding the detection and reporting of preterm labor symptomatology
Number of subjects: 0
Study 698029 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam 5 mg
Number of subjects: 78
Study 698029 — intervention group
Group type: COMPARATOR
Intervention: Control/Placebo
Number of subjects: 78
Study 31633254 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 30
Study 31633254 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 30
Study 31633254 — intervention group
Group type: COMPARATOR
Intervention: Ketamine and Midazolam (comparison)
Number of subjects: 30
Study 31212248 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (∼1 μg L‐1)
Number of subjects: 0
Study 31212248 — intervention group
Group type: EXPERIMENTAL
Intervention: Methamphetamine (∼1 μg L‐1)
Number of subjects: 0
Study 31212248 — intervention group
Group type: COMPARATOR
Intervention: Control (unexposed)
Number of subjects: 0
Study 29492054 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent cervical traction in sitting position along with TENS and hot pack (Group-A)
Number of subjects: 40
Study 29492054 — intervention group
Group type: COMPARATOR
Intervention: Intermittent cervical traction in supine position along with TENS and hot pack (Group-B)
Number of subjects: 40
Study 27506203 — intervention group
Group type: EXPERIMENTAL
Intervention: Reinforcement-Induced Movement Therapy (RIMT) with goal-oriented movement amplification in VR
Number of subjects: 18
Study 27506203 — intervention group
Group type: COMPARATOR
Intervention: Control group with the same training protocol but without movement amplification
Number of subjects: 18
Study 24824360 — intervention group
Group type: EXPERIMENTAL
Intervention: Tryptophan intake of 15 mg·kg·day
Number of subjects: 30
Study 24824360 — intervention group
Group type: EXPERIMENTAL
Intervention: Elemental formula
Number of subjects: 30
Study 24824360 — intervention group
Group type: COMPARATOR
Intervention: Recommended intake of 29 mg·kg·day
Number of subjects: 30
Study 23227501 — intervention group
Group type: EXPERIMENTAL
Intervention: Remaxol
Number of subjects: 120
Study 23227501 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 20089937 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate 25 mg/kg/d
Number of subjects: 149
Study 20089937 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate 15 mg/kg/d
Number of subjects: 149
Study 20089937 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate 5 mg/kg/d
Number of subjects: 149
Study 20089937 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 149
Study 18975532 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane with nitrous oxide (Group G)
Number of subjects: 20
Study 18975532 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane with air (Group A)
Number of subjects: 20
Study 15983916 — intervention group
Group type: COMPARATOR
Intervention: Therapeutic interleukin-2
Number of subjects: 0
Study 15983916 — intervention group
Group type: COMPARATOR
Intervention: High-dose prednisolone
Number of subjects: 0
Study 15983916 — intervention group
Group type: COMPARATOR
Intervention: Etanercept (a soluble TNF receptor)
Number of subjects: 0
Study 15983916 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-TNF antibody infliximab
Number of subjects: 0
Study 15983916 — intervention group
Group type: COMPARATOR
Intervention: Antiretroviral therapy
Number of subjects: 0
Study 11915001 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% adherence
Number of subjects: 0
Study 11915001 — intervention group
Group type: EXPERIMENTAL
Intervention: 80%-99% adherence
Number of subjects: 0
Study 11915001 — intervention group
Group type: EXPERIMENTAL
Intervention: 0%-79% adherence
Number of subjects: 0
Study 11915001 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% adherence at 3 follow-up visits
Number of subjects: 0
Study 11915001 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% adherence at 2 follow-up visits
Number of subjects: 0
Study 11915001 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% adherence at 1 follow-up visit
Number of subjects: 0
Study 11915001 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% adherence at 0 follow-up visits
Number of subjects: 0
Study 10037565 — intervention group
Group type: EXPERIMENTAL
Intervention: Entoptic perimetry
Number of subjects: 32
Study 10037565 — intervention group
Group type: COMPARATOR
Intervention: Fundus photography
Number of subjects: 32
Study 7744158 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedation only
Number of subjects: 46
Study 7744158 — intervention group
Group type: COMPARATOR
Intervention: Operating room setting
Number of subjects: 46
Study 1481832 — intervention group
Group type: EXPERIMENTAL
Intervention: Folinic acid (dl-Leucovorin, 15 mg/day)
Number of subjects: 21
Study 1481832 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 4096357 — intervention group
Group type: EXPERIMENTAL
Intervention: TTS-scopolamine
Number of subjects: 40
Study 4096357 — intervention group
Group type: COMPARATOR
Intervention: TTS-placebo
Number of subjects: 40
Study 31216086 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir-velpatasvir (400/100 mg) once daily for 12 weeks
Number of subjects: 111
Study 29693533 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist emails rated for adherence and quality
Number of subjects: 91
Study 29693533 — intervention group
Group type: EXPERIMENTAL
Intervention: ICBT-TRS ratings
Number of subjects: 91
Study 27113490 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat diet
Number of subjects: 733
Study 27113490 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat diet
Number of subjects: 733
Study 27113490 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall genetic risk score (GRS)
Number of subjects: 733
Study 27113490 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary fat interaction
Number of subjects: 733
Study 24813819 — intervention group
Group type: EXPERIMENTAL
Intervention: Mailed access to FIT and colonoscopy
Number of subjects: 945
Study 24813819 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone navigation for FIT and colonoscopy
Number of subjects: 945
Study 24813819 — intervention group
Group type: EXPERIMENTAL
Intervention: Preference for FIT
Number of subjects: 945
Study 24813819 — intervention group
Group type: EXPERIMENTAL
Intervention: Preference for colonoscopy
Number of subjects: 945
Study 24152757 — intervention group
Group type: EXPERIMENTAL
Intervention: Behaviour change intervention
Number of subjects: 478
Study 20636488 — intervention group
Group type: EXPERIMENTAL
Intervention: Tecnis Z9003(®) (Group A)
Number of subjects: 90
Study 20636488 — intervention group
Group type: EXPERIMENTAL
Intervention: Acrysof IQ SN60WF(®) (Group B)
Number of subjects: 90
Study 20636488 — intervention group
Group type: EXPERIMENTAL
Intervention: Akreos ADAPT‐AO(®) (Group C)
Number of subjects: 90
Study 20636488 — intervention group
Group type: COMPARATOR
Intervention: All groups (A, B, C)
Number of subjects: 90
Study 19056576 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsinoids (6 mg/d)
Number of subjects: 80
Study 19056576 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 17179252 — intervention group
Group type: EXPERIMENTAL
Intervention: Cobra Perilaryngeal Airway (CobraPLA)
Number of subjects: 40
Study 17179252 — intervention group
Group type: COMPARATOR
Intervention: Laryngeal Mask Airway (LMA)‐Classic
Number of subjects: 40
Study 15559606 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN‐beta 1‐a
Number of subjects: 47
Study 15559606 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN‐beta 1‐b
Number of subjects: 47
Study 15559606 — intervention group
Group type: EXPERIMENTAL
Intervention: Both preparations of IFN‐beta 1‐a
Number of subjects: 47
Study 15559606 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 47
Study 11521785 — intervention group
Group type: EXPERIMENTAL
Intervention: AC + EP (adriamycin + cyclophosphamide + etoposide + cisplatin)
Number of subjects: 162
Study 11521785 — intervention group
Group type: COMPARATOR
Intervention: AC (adriamycin + cyclophosphamide)
Number of subjects: 162
Study 9716578 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 325 mg/d
Number of subjects: 16
Study 9716578 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticlopidine 500 mg/d
Number of subjects: 16
Study 9716578 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 325 mg/d + Ticlopidine 500 mg/d
Number of subjects: 16
Study 9716578 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 7593999 — intervention group
Group type: EXPERIMENTAL
Intervention: Health promotion program with physical fitness and exercise components
Number of subjects: 0
Study 7593999 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 2169780 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 40 micrograms/kg
Number of subjects: 443
Study 2169780 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 160 micrograms/kg
Number of subjects: 443
Study 2169780 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 40 micrograms/kg (additional doses allowed)
Number of subjects: 443
Study 2169780 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron (both doses)
Number of subjects: 443
Study 7021163 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchodilator aerosol with tube extension (terbutaline sulphate 0.25 mg)
Number of subjects: 12
Study 7021163 — intervention group
Group type: COMPARATOR
Intervention: Ordinary aerosol
Number of subjects: 12
Study 31029045 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher cocoa chocolate (HCC; ∼90%; 20 g daily)
Number of subjects: 30
Study 31029045 — intervention group
Group type: COMPARATOR
Intervention: Lower cocoa chocolate (LCC; ∼55%; 20 g daily)
Number of subjects: 30
Study 28652048 — intervention group
Group type: EXPERIMENTAL
Intervention: Active low-intensity vibration (LIV) device
Number of subjects: 30
Study 28652048 — intervention group
Group type: COMPARATOR
Intervention: Placebo LIV device
Number of subjects: 30
Study 26395498 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard dressings
Number of subjects: 460
Study 26395498 — intervention group
Group type: COMPARATOR
Intervention: Negative pressure wound therapy
Number of subjects: 460
Study 23228972 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg nebivolol per day for 3 months
Number of subjects: 35
Study 21492495 — intervention group
Group type: EXPERIMENTAL
Intervention: Solid food form (12.5% of energy need)
Number of subjects: 34
Study 21492495 — intervention group
Group type: COMPARATOR
Intervention: Beverage food form (12.5% of energy need)
Number of subjects: 34
Study 21492495 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training (RT)
Number of subjects: 34
Study 21492495 — intervention group
Group type: COMPARATOR
Intervention: Sedentary (Sed)
Number of subjects: 34
Study 21492495 — intervention group
Group type: EXPERIMENTAL
Intervention: Solid food form
Number of subjects: 34
Study 21492495 — intervention group
Group type: COMPARATOR
Intervention: Beverage food form
Number of subjects: 34
Study 21492495 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training (RT) and food form (FFNS)
Number of subjects: 34
Study 19701512 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil S3 Bond (irradiated)
Number of subjects: 84
Study 19701512 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond (irradiated)
Number of subjects: 84
Study 19701512 — intervention group
Group type: EXPERIMENTAL
Intervention: Prime & Bond NT (irradiated)
Number of subjects: 84
Study 19701512 — intervention group
Group type: COMPARATOR
Intervention: Clearfil S3 Bond (nonirradiated)
Number of subjects: 84
Study 19701512 — intervention group
Group type: COMPARATOR
Intervention: Clearfil SE Bond (nonirradiated)
Number of subjects: 84
Study 19701512 — intervention group
Group type: COMPARATOR
Intervention: Prime & Bond NT (nonirradiated)
Number of subjects: 84
Study 16814981 — intervention group
Group type: EXPERIMENTAL
Intervention: OCI-R subscales for OCD patients
Number of subjects: 203
Study 16814981 — intervention group
Group type: EXPERIMENTAL
Intervention: OCI-R scores for patients acknowledging symptom subtype as present but not primary on the Y-BOCS
Number of subjects: 203
Study 16814981 — intervention group
Group type: EXPERIMENTAL
Intervention: OCI-R subscales
Number of subjects: 203
Study 16814981 — intervention group
Group type: EXPERIMENTAL
Intervention: OCI-R
Number of subjects: 203
Study 14734063 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (25mg/ml) treatment for 5 minutes
Number of subjects: 15
Study 14734063 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 15